Figure 3.

5FU followed by p50-IMC slows PCa tumor growth. (A) Mice inoculated SQ with Hi-Myc PCa on day 0 received 5FU on day 13 and 1×10⁷ WT-IMC or p50-IMC on days 18, 21 and 25, as diagrammed. Additional groups of mice received 5FU alone, no treatment or p50-IMC alone. Individual tumor volumes as measured every 2–4 days are shown. Results are combined from two to four experiments. (B) These data were fit to an exponential model, with semilog plots and comparison of expected mean tumor volumes between the 5FU/p50-IMC and 5FU/WT-IMC, 5FU-alone or p50-IMC-alone groups on day 29. (C) Mean tumor volumes and SEs as measured on day 29 (or day 28) for 5FU, 5FU/WT-IMC and 5FU/p50-IMC mice (top) and on day 25 for no treatment (--), p50-IMC and 5FU/p50-IMC are shown, along with the number of mice with measurable tumors in each group on those days. 5FU, 5-fluorouracil; IMC, immature myeloid cell; p50-IMC, p50-negative immature myeloid cell; PCa, prostate cancer; SQ, subcutaneous; WT, wild type.